Gabapentin (All indications) updated on 04-22-2025

Hypospadias

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S19321
R81887		 Kim (Controls exposed to LTG) (Gabapentin) (Indications NOS), 2026 Hypospadias 1st trimester population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 1.91 [0.20;18.37] C
excluded (control group) 		3/1,131   1/718 4 1,131
ref
S19313
R81786		 Kim (Controls unexposed, NOS) (Gabapentin) (Indications NOS), 2026 Hypospadias 1st trimester population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes 1.80 [0.45;7.21] 3/1,131   2,427/2,489,078 2,430 1,131
ref
S10033
R36117		 Blotière (Controls exposed to Lamotrigine, sick) (Other indications), 2019 Hypospadias 1st trimester retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: No Controls: mixed indications 1.17 [0.14;9.57] C
excluded (control group) 		1/365   7/2,997 8 365
ref
S10034
R36140		 Blotière (Controls unexposed NOS) (Other indications), 2019 Hypospadias 1st trimester retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No 1.53 [0.21;10.87] C 1/365   3,371/1,875,733 3,372 365
ref
S8493
R27901		 Morrow (Controls exposed to Lamotrigine, sick), 2006 Hypospadias/genitourinary tract defects 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 1.62 [0.09;29.34] C 0/31   6/647 6 31
ref
Total 3 studies 1.69 [0.59;4.86] 5,808 1,527
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Kim (Controls unexposed, NOS) (Gabapentin) (Indications NOS), 2026Kim, 2026 1 1.80[0.45; 7.21]2,4301,13158%ROB confusion: seriousROB selection: lowROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Blotière (Controls unexposed NOS) (Other indications), 2019Blotière, 2019 2 1.53[0.21; 10.87]3,37236529%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Morrow (Controls exposed to Lamotrigine, sick), 2006Morrow, 2006 3 1.62[0.09; 29.34]63113%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (3 studies) I2 = 0% 1.69[0.59; 4.86]5,8081,5270.55.01.0ROB: A: confounding, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, NOS) (Gabapentin) (Indications NOS; 2: Controls unexposed NOS) (Other indications; 3: Controls exposed to Lamotrigine, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.69[0.59; 4.86]5,8081,5270%NAKim (Controls unexposed, NOS) (Gabapentin) (Indications NOS), 2026 Blotière (Controls unexposed NOS) (Other indications), 2019 Morrow (Controls exposed to Lamotrigine, sick), 2006 3 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.70[0.55; 5.29]5,8021,4960%NAKim (Controls unexposed, NOS) (Gabapentin) (Indications NOS), 2026 Blotière (Controls unexposed NOS) (Other indications), 2019 2 exposed to other treatment, sickexposed to other treatment, sick 1.62[0.09; 29.34]631 -NAMorrow (Controls exposed to Lamotrigine, sick), 2006 1 Tags Adjustment   - No  - No 1.55[0.31; 7.89]3,3783960%NABlotière (Controls unexposed NOS) (Other indications), 2019 Morrow (Controls exposed to Lamotrigine, sick), 2006 2   - Yes  - Yes 1.80[0.45; 7.20]2,4301,131 -NAKim (Controls unexposed, NOS) (Gabapentin) (Indications NOS), 2026 1 All studiesAll studies 1.69[0.59; 4.86]5,8081,5270%NAKim (Controls unexposed, NOS) (Gabapentin) (Indications NOS), 2026 Blotière (Controls unexposed NOS) (Other indications), 2019 Morrow (Controls exposed to Lamotrigine, sick), 2006 30.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 10033, 19321

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.70[0.55; 5.29]5,8021,4960%NAKim (Controls unexposed, NOS) (Gabapentin) (Indications NOS), 2026 Blotière (Controls unexposed NOS) (Other indications), 2019 2 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.50[0.39; 5.84]181,5270%NAKim (Controls exposed to LTG) (Gabapentin) (Indications NOS), 2026 Blotière (Controls exposed to Lamotrigine, sick) (Other indications), 2019 Morrow (Controls exposed to Lamotrigine, sick), 2006 3 design cohort studycohort study 1.69[0.59; 4.86]5,8081,5270%NAKim (Controls unexposed, NOS) (Gabapentin) (Indications NOS), 2026 Blotière (Controls unexposed NOS) (Other indications), 2019 Morrow (Controls exposed to Lamotrigine, sick), 2006 3 case controlcase control 0 case-time-controlcase-time-control 0 case-case-time-controlcase-case-time-control 0 otherother 00.510.01.0

Umbrella review (other published meta-analyses)

Published MAControlPeriodTE95% CIn exposedkI2 Veroniki a (MA) (All indications) (Hypospadias)Veroniki a (MA) (All indications) (Hypospadias) Out of scale4096.00[36.18; 193000.00]NA-Wwhatever (meta-analysis)T11st trimesterstudies TTT1 Veroniki a (NMA) (All indications) (Hypospadias)Veroniki a (NMA) (All indications) (Hypospadias) Out of scale16.54[2.50; 121.70]NA-Wwhatever (meta-analysis)T11st trimesterstudies TTT-9 metaPregmetaPreg 1.69[0.59; 4.86]0%1,527----Kim (Controls unexposed, NOS) (Gabapentin) (Indications NOS), 2026 Blotière (Controls unexposed NOS) (Other indications), 2019 Morrow (Controls exposed to Lamotrigine, sick), 2006 30.510.01.0